Dupixent t-cell lymphoma lawsuit claims continue to grow as patients allege the popular medication caused them to develop rare and aggressive blood cancers. Dupixent (dupilumab) is manufactured by Sanofi and Regeneron Pharmaceuticals. The drug treats conditions like eczema, asthma, and chronic sinusitis. However, plaintiffs claim the companies failed to warn about a serious cancer risk. Patients who developed cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) after using Dupixent are now seeking accountability through the federal court system.
Case Timeline
Last checked: June 04, 2026
What Is the Dupixent T-Cell Lymphoma Lawsuit About?
Dupixent is a biologic drug that blocks two inflammatory proteins: interleukin-4 (IL-4) and interleukin-13 (IL-13). The FDA has approved it for multiple conditions. These include moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Millions of patients have used the drug since its initial approval in 2017.
The dupixent t-cell lymphoma lawsuit centers on allegations that the drug masks, triggers, or accelerates rare T-cell lymphomas. Research published between 2024 and 2025 found that CTCL reports were approximately 30 times higher for Dupixent users compared to all other medications. In most cases, early CTCL symptoms closely mimic eczema. As a result, patients and doctors may not recognize the cancer until it has progressed significantly.
Plaintiffs allege that Sanofi and Regeneron knew or should have known about this elevated risk. In March 2025, the FDA placed Dupixent on its quarterly FAERS “Potential Signals” list for cutaneous T-cell lymphoma. The agency confirmed it is evaluating the need for regulatory action following at least 300 reported cases. The dupixent t-cell lymphoma lawsuit alleges the manufacturers failed to update warnings despite mounting evidence of harm.
MDL Case Status and Key Facts
| Detail | Information |
|---|---|
| MDL Number | 3180 |
| Full Name | IN RE: Dupixent (Dupilumab) Products Liability Litigation |
| Presiding Judge | Pending — JPML ruling expected |
| Proposed Federal District | N.D. Georgia (plaintiffs) / S.D. New York (defendants) |
| Approximate Case Count | 15+ federal lawsuits in 12 districts |
| Centralization Motion Filed | February 13, 2026 |
| JPML Oral Arguments | May 28, 2026 (Milwaukee, WI) |
| Bellwether Trials | Not yet scheduled |
The U.S. Judicial Panel on Multidistrict Litigation (JPML) heard oral arguments on May 28, 2026 regarding centralization. Both sides agree the cases should be consolidated into a single MDL. However, they disagree on venue. Plaintiffs proposed the Northern District of Georgia, where four cases are already pending. Sanofi and Regeneron argued for the Southern District of New York, where both companies are headquartered.
A ruling from the JPML is expected in the coming weeks. Once a judge is assigned, the dupixent t-cell lymphoma lawsuit will enter the pretrial discovery phase. This typically includes document production, expert depositions, and the selection of bellwether cases for trial. The litigation is still in its early stages, and no trial dates have been set.
Who Qualifies for the Dupixent T-Cell Lymphoma Lawsuit?
You may qualify for a dupixent t-cell lymphoma lawsuit if you used Dupixent and were later diagnosed with a T-cell lymphoma. Qualifying diagnoses typically include cutaneous T-cell lymphoma (CTCL), mycosis fungoides, Sézary syndrome, or peripheral T-cell lymphoma (PTCL). The diagnosis must have occurred during or after Dupixent treatment.
In most cases, attorneys look for patients who used Dupixent for conditions like eczema or asthma. The initial symptoms of CTCL often resemble atopic dermatitis. For example, persistent skin rashes, plaques, or lesions that did not respond to treatment may have been early signs of lymphoma. Patients who experienced a worsening or changing skin condition while on Dupixent should consult a licensed attorney to evaluate their case.
Evidence that may strengthen a dupixent t-cell lymphoma lawsuit claim includes medical records showing Dupixent prescriptions, pathology reports confirming a T-cell lymphoma diagnosis, and documentation of the timeline between drug use and cancer onset. Family members of patients who died from T-cell lymphoma after using Dupixent may also be eligible to file a wrongful death claim. The first wrongful death lawsuit was filed in Tennessee in October 2025.
How to File a Dupixent T-Cell Lymphoma Lawsuit Claim
Filing a dupixent t-cell lymphoma lawsuit begins with consulting a mass tort attorney experienced in pharmaceutical litigation. Most attorneys offer free case evaluations. They work on a contingency fee basis, meaning you pay nothing unless your case results in compensation. An attorney can review your medical history and determine whether your diagnosis qualifies.
Once retained, your attorney will gather medical records and prepare a complaint. If the MDL is established, your case will likely be transferred to the assigned federal court. You will need to complete a plaintiff fact sheet. This document provides detailed information about your Dupixent use, medical history, diagnosis, and treatment. Accuracy on this form is critical to moving your case forward.
Statutes of limitations vary by state. Typically, you have two to three years from the date of diagnosis or discovery of the injury to file a claim. However, some states have shorter deadlines. As a result, it is important to act promptly. You should consult a licensed attorney in your state to understand the specific filing deadline that applies to your situation.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Settlement Updates and What to Expect
As of June 2026, there have been no settlements or jury verdicts in the dupixent t-cell lymphoma lawsuit. The litigation is still in its earliest stages. Centralization has not yet been formally ordered, and discovery has not begun. Settlement negotiations typically do not start until after bellwether trials produce results.
In similar pharmaceutical MDLs, the process from centralization to bellwether trials takes approximately two to four years. Settlement values in the dupixent t-cell lymphoma lawsuit will depend on several factors. These include the severity of the cancer diagnosis, the strength of the causal connection to Dupixent, the patient’s age, and the extent of medical expenses and lost income.
Plaintiffs should be aware that mass tort cases require patience. However, the fact that both sides agreed on centralization is a positive sign. It suggests the litigation will proceed efficiently. Bellwether trials will help establish the range of potential outcomes. Individual settlement amounts will vary based on the unique facts of each case. You should consult with your attorney about realistic expectations for your specific claim.
State-by-State Considerations
While the dupixent t-cell lymphoma lawsuit is being consolidated at the federal level, state laws still affect individual claims. Each state has its own statute of limitations, damage caps, and rules about evidence. For example, states like Georgia, New York, Tennessee, California, and Florida have seen notable plaintiff filings in this litigation. Tort reform laws in some states may limit non-economic damages or impose other restrictions on recovery.
After the MDL concludes pretrial proceedings, cases that do not settle may be remanded back to their original state courts for trial. At that point, local laws will play a significant role in determining outcomes. You can learn more about how your state’s laws affect mass tort claims by visiting our state-by-state tort reform guide. Understanding these differences is important when evaluating the potential value of your dupixent t-cell lymphoma lawsuit.
Frequently Asked Questions
What types of cancer are linked to Dupixent in these lawsuits?
The dupixent t-cell lymphoma lawsuit primarily involves cutaneous T-cell lymphoma (CTCL), including subtypes like mycosis fungoides and Sézary syndrome. Some cases also involve peripheral T-cell lymphoma (PTCL). These are rare cancers of the immune system that affect the skin and lymph nodes.
How long do I have to file a Dupixent lawsuit?
Statutes of limitations vary by state but typically range from two to four years. The clock usually starts from the date of diagnosis or when you discovered the connection to Dupixent. Because deadlines differ, you should consult a licensed attorney promptly to avoid missing your filing window.
Is it too late to join the dupixent t-cell lymphoma lawsuit?
No, it is not too late. The MDL is still being formed, and new cases continue to be filed. Attorneys are actively accepting new clients who meet the eligibility criteria. However, you should not delay. Acting quickly ensures your claim is preserved and your evidence is fresh. Contact a qualified mass tort attorney to discuss your options.
Check If You May Qualify
Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.
Official Sources & Resources
For verified mass tort and MDL information:
- U.S. Judicial Panel on Multidistrict Litigation (JPML)
- U.S. Department of Justice
- FDA Safety Alerts & Recalls
- Centers for Disease Control and Prevention
- U.S. Environmental Protection Agency
Content last reviewed June 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.
Related Guides
- All Active MDL Cases
- More in This Category
- Tort Reform by State — 50-State Comparison
- All 50 State Tort Reform Guides
- Mass Tort Explainers
- Demographic Guides
- Mass Tort Tips
- Illinois Tort Reform Guide
- Texas Tort Reform Guide
- Ohio Tort Reform Guide
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.